Estrogen and Progesterone Therapy and Meningiomas

Endocrinology. 2022 Feb 1;163(2):bqab259. doi: 10.1210/endocr/bqab259.

Abstract

Meningiomas are common intracranial tumors with a female predominance. Their etiology is still poorly documented. The role of sexual hormones has long been evoked, and data have been conflicting across studies. However, a dose-dependent relationship between the incidence and growth of meningiomas and hormonal treatment with the progestin cyproterone acetate (CPA) has recently been established. CPA-associated meningiomas seem to be mainly located in the anterior and middle skull base, are more likely to be multiple, may harbor P1K3CA mutations in up to one-third of cases, and are more common with a longer duration of treatment. A similar but lower risk of meningiomas has been recently reported with the use of chlormadinone acetate and nomegestrol acetate as progestin treatments. Concerning hormonal replacement therapy (HRT) in menopausal patients, evidence from epidemiological studies seem to favor an increased risk of meningiomas in treated patients although a recent study failed to show an increased growth of meningiomas in HRT treated vs nontreated patients. Until larger studies are available, it seems wise to recommend avoiding HRT in patients with meningiomas. Evidence from published data does not seem to support an increased risk of meningiomas with oral contraceptive oral contraceptive (OR) use. Data are too scarce to conclude on fertility treatments. Based on studies demonstrating the expression of hormonal receptors in meningiomas, therapies targeting these receptors have been tried but have failed to show an overall favorable clinical outcome in meningioma treatment.

Keywords: cyproterone acetate; hormonal replacement therapy; meningiomas; oral contraception.

Publication types

  • Review

MeSH terms

  • Contraceptives, Oral, Hormonal / adverse effects
  • Cyproterone Acetate / adverse effects
  • Dose-Response Relationship, Drug
  • Estrogen Replacement Therapy / adverse effects
  • Estrogens / adverse effects*
  • Estrogens / therapeutic use
  • Female
  • Humans
  • Male
  • Meningeal Neoplasms / chemically induced*
  • Meningeal Neoplasms / epidemiology*
  • Meningeal Neoplasms / pathology
  • Meningioma / chemically induced*
  • Meningioma / epidemiology*
  • Meningioma / pathology
  • Postmenopause
  • Progesterone / adverse effects*
  • Progesterone / therapeutic use
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis

Substances

  • Contraceptives, Oral, Hormonal
  • Estrogens
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Progesterone
  • Cyproterone Acetate